Ä¢¹½ÊÓƵ

MITSUBISHI CHEMICAL GROUP
MITSUBISHI CHEMICAL GROUP

COVID-19 vaccine, ¡°COVIFENZ® ¡± (MT-2766) has been approved in Canada

February 24, 2022

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President: Hiroaki Ueno), an operating company of Mitsubishi Chemical Holdings Corporation (Head Office: Tokyo; President: Jean-Marc Gilson) announced that Health Canada has granted full approval for COVIFENZ® (COVID-19 vaccine, plant-based virus-like particles [VLP], project code: MT-2766) on February 24.

Mitsubishi Tanabe Pharma¡¡Press Release

?Information is current as of the date of issue of the individual press release. Please be advised that information may be outdated after that point.

Back to top